STAB Key Statistics, Chart & Performance
The current stock price of STAB is 0.0911 USD. In the past month the price decreased by -20.09%. In the past year, price decreased by -95.38%.
STAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About STAB
Company Profile
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
Company Info
STATERA BIOPHARMA INC
2537 Research Boulevard, Suite 201
Fort Collins COLORADO US
CEO: Christopher Zosh
Employees: 46
Phone: 18886138802.0
STATERA BIOPHARMA INC / STAB FAQ
What does STAB do?
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
What is the stock price of STATERA BIOPHARMA INC today?
The current stock price of STAB is 0.0911 USD. The price decreased by -5.2% in the last trading session.
Does STATERA BIOPHARMA INC pay dividends?
STAB does not pay a dividend.
What is the ChartMill technical and fundamental rating of STAB stock?
STAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is STATERA BIOPHARMA INC (STAB) stock traded?
STAB stock is listed on the Nasdaq exchange.
How many employees does STATERA BIOPHARMA INC have?
STATERA BIOPHARMA INC (STAB) currently has 46 employees.
Can you provide the ownership details for STAB stock?
You can find the ownership structure of STATERA BIOPHARMA INC (STAB) on the Ownership tab.
STAB Technical Analysis
STAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STAB. STAB has a bad profitability rating. Also its financial health evaluation is rather negative.
STAB Financial Highlights
Over the last trailing twelve months STAB reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -71.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |